The Online Investor
Matinas BioPharma Holdings Inc (MTNB)

Matinas Biopharma Holdings is a biopharmaceutical company focused on its product candidate: MAT9001, a purified, prescription-only omega-3 free fatty acid formulation designed for the treatment of cardiovascular and metabolic conditions; and the application of its lipid nano-crystal (LNC) platform delivery technology to solve challenges relating to the delivery of small molecules, gene therapies, vaccines, proteins and peptides. Co.'s LNC platform product candidate, MAT2203, is an orally-administered LNC formulation of an anti-fungal drug. Co.'s second clinical stage LNC-based product candidate is MAT2501, an orally administered, cochleate formulation of aminoglycoside antibiotic amikacin.
Company Name: 
Matinas BioPharma Holdings Inc
Drugs & Pharmaceuticals
Number of ETFs Holding MTNB: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
88th percentile
(ranked higher than approx. 88% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Matinas BioPharma Holdings Inc (MTNB) Page | The Online Investor Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.